



Editas Medicine announces CEO Transition

23 January 2019 | News

Katrine Bosley to Step Down as President and CEO



Genome editing company, Editas Medicine has announced that Katrine Bosley has decided to step down from her role as President and CEO, effective March 1, 2019.

Bosley has also resigned from the Company's Board of Directors. The Board has appointed Cynthia Collins, a member of the Company's Board, as interim Chief Executive Officer.

The Board has initiated a search process to identify a permanent CEO and has retained Heidrick & Struggles, executive search firm, to assist in its efforts. Bosley will continue with the Company in an advisory capacity until the end of 2019 to facilitate a smooth transition.

James C. Mullen, Chairman of the Board of Directors, Editas said, "On behalf of the entire Board, I thank Katrine for her more than four years of dedicated service to Editas Medicine. Under her leadership, the Company achieved significant growth, hitting key milestones in the EDIT-101 clinical program and developing the Company's transformative engineered cell medicines. She has helped establish Editas Medicine as a leading genome editing company with a strong foundation, well positioned to achieve its long-term goals and deliver the potential of genome editing to patients around the world."

“Editas Medicine has strong positive momentum with the potential to deliver important genome editing medicines to patients around the world. We are fortunate to have someone with Cindy’s proven leadership and significant experience with genomic medicine to take over the day-to-day leadership of Editas Medicine and advance the Company towards its EM22 goals while the CEO search is ongoing”, he added.

Collins commented, “I’m honored to take on the role of interim CEO during this important time for the Company. I look forward to working closely with Katrine and the talented Editas Medicine team to build on the momentum of the Company’s recent successes, push the pace of innovation and accelerate our achievements for the benefit of those living with serious diseases.”

Bosley said, “The team at Editas Medicine is making the future of medicine a reality. I’m very proud of them and all they have accomplished. I know they will keep driving forward to make unprecedented medicines to help people with serious diseases, and ones that may truly change patients’ lives. It has been a privilege to be part of Editas Medicine and to help pioneer this field, and I look forward to their continued success.”

Cynthia Collins joined the Editas Medicine Board of Directors in December 2018. Most recently, she served as CEO of Human Longevity Inc. Prior, she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clariant Diagnostics.